Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Liu

Showing results (161-170 of 574) with videos related to

Pageof 58
Sort By:
Clinical Lung Cancer|November 22, 2024
A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung CancerSze Wah Samuel Chan, Joy Zeng, Jack Young, et al.
Lung Cancer (Amsterdam, Netherlands)|June 5, 2017
Uncommon EGFR mutations in advanced non-small cell lung cancerGrainne M O'Kane, Penelope A Bradbury, Ronald Feld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcomeMichael Lanuti, Geoffrey Liu, Jonathan M Goodwin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2012
Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysisLawson Eng, Abul Kalam Azad, Steven Habbous, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 6, 2011
Pharmacogenetic and germline prognostic markers of lung cancerAnne M Horgan, Boming Yang, Abul Kalam Azad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancerRebecca Suk Heist, Wei Zhou, Lucian R Chirieac, et al.
Therapeutic Advances in Medical Oncology|November 22, 2021
The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancerBarbara Melosky, Parneet Cheema, Rosalyn A Juergens, et al.
Cancer Letters|August 28, 2004
MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinomaGeoffrey Liu, Wei Zhou, Lisa I Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2026
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitorsGeoffrey Liu, Devin Abrahami, Priya Ramachandran, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Genetic polymorphisms and head and neck cancer outcomes: a reviewJessica Hopkins, David W Cescon, Darren Tse, et al.
Pageof 58

Showing results (161-170 of 574) with videos related to

Sort By:
Pageof 58
Clinical Lung Cancer|November 22, 2024
A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung CancerSze Wah Samuel Chan, Joy Zeng, Jack Young, et al.
Lung Cancer (Amsterdam, Netherlands)|June 5, 2017
Uncommon EGFR mutations in advanced non-small cell lung cancerGrainne M O'Kane, Penelope A Bradbury, Ronald Feld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcomeMichael Lanuti, Geoffrey Liu, Jonathan M Goodwin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2012
Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysisLawson Eng, Abul Kalam Azad, Steven Habbous, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 6, 2011
Pharmacogenetic and germline prognostic markers of lung cancerAnne M Horgan, Boming Yang, Abul Kalam Azad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancerRebecca Suk Heist, Wei Zhou, Lucian R Chirieac, et al.
Therapeutic Advances in Medical Oncology|November 22, 2021
The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancerBarbara Melosky, Parneet Cheema, Rosalyn A Juergens, et al.
Cancer Letters|August 28, 2004
MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinomaGeoffrey Liu, Wei Zhou, Lisa I Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2026
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitorsGeoffrey Liu, Devin Abrahami, Priya Ramachandran, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Genetic polymorphisms and head and neck cancer outcomes: a reviewJessica Hopkins, David W Cescon, Darren Tse, et al.
Pageof 58